| pubmed-article:8445035 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8445035 | lifeskim:mentions | umls-concept:C0029944 | lld:lifeskim |
| pubmed-article:8445035 | lifeskim:mentions | umls-concept:C0020459 | lld:lifeskim |
| pubmed-article:8445035 | lifeskim:mentions | umls-concept:C0020615 | lld:lifeskim |
| pubmed-article:8445035 | lifeskim:mentions | umls-concept:C0028833 | lld:lifeskim |
| pubmed-article:8445035 | lifeskim:mentions | umls-concept:C0038766 | lld:lifeskim |
| pubmed-article:8445035 | lifeskim:mentions | umls-concept:C1555029 | lld:lifeskim |
| pubmed-article:8445035 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:8445035 | lifeskim:mentions | umls-concept:C1292733 | lld:lifeskim |
| pubmed-article:8445035 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8445035 | pubmed:dateCreated | 1993-4-5 | lld:pubmed |
| pubmed-article:8445035 | pubmed:abstractText | Emergency therapy of sulfonylurea overdoses with glucose is often unsatisfactory because glucose stimulates insulin release and initiates a need for escalating quantities of hypertonic glucose to maintain normoglycemia. We tested the hypothesis that octreotide, an analog of somatostatin, would reverse hyperinsulinemia induced by a sulfonylurea overdose. Eight normal subjects received glipizide (1.45 mg/kg) on three occasions. Within 3 h, all subjects became hypoglycemic (< 50 mg/dL) and were initially treated with 50% dextrose followed by 1) dextrose infusion, 2) octreotide (30 ng/kg.min, iv), or 3) diazoxide (300 mg, iv, every 4 h). Euglycemia (85 mg/dL) was maintained with supplementary dextrose in treatment limbs 2 and 3. Insulin concentrations were 4-5 times greater with dextrose alone or in combination with diazoxide than with octreotide (P < 0.01). Dextrose requirements during diazoxide or dextrose alone were not different, but were both greater than those during octreotide treatment (P < 0.0001). All therapies were stopped at 13 h. Glucose levels remained above 3.6 mmol/L (65 mg/dL) in six of eight subjects receiving octreotide for the remaining 4 h. Glucose fell to below 3.6 mmol/L within 1.5 h of stopping either dextrose or diazoxide in each subject. Overall, octreotide reduced and in four of eight subjects entirely eliminated the need for exogenous glucose after a large overdose of glipizide. We conclude that octreotide is safe and effective and should be strongly considered as a logical therapeutic alternative for this metabolic emergency. | lld:pubmed |
| pubmed-article:8445035 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445035 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8445035 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445035 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8445035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445035 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445035 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8445035 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8445035 | pubmed:issn | 0021-972X | lld:pubmed |
| pubmed-article:8445035 | pubmed:author | pubmed-author:SchadeD SDS | lld:pubmed |
| pubmed-article:8445035 | pubmed:author | pubmed-author:BoyleP JPJ | lld:pubmed |
| pubmed-article:8445035 | pubmed:author | pubmed-author:KrentzA JAJ | lld:pubmed |
| pubmed-article:8445035 | pubmed:author | pubmed-author:NeetM RMR | lld:pubmed |
| pubmed-article:8445035 | pubmed:author | pubmed-author:JusticeKK | lld:pubmed |
| pubmed-article:8445035 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8445035 | pubmed:volume | 76 | lld:pubmed |
| pubmed-article:8445035 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8445035 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8445035 | pubmed:pagination | 752-6 | lld:pubmed |
| pubmed-article:8445035 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:meshHeading | pubmed-meshheading:8445035-... | lld:pubmed |
| pubmed-article:8445035 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8445035 | pubmed:articleTitle | Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. | lld:pubmed |
| pubmed-article:8445035 | pubmed:affiliation | Department of Medicine, University of New Mexico School of Medicine, Albuquerque 87131-5271. | lld:pubmed |
| pubmed-article:8445035 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8445035 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8445035 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8445035 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8445035 | lld:pubmed |
